Aslan Pharmaceuticals Received $12M From Zenyaku Kogyo Co. As Upfront Payment Pursuant To Strategic Licensing Agreement
Portfolio Pulse from Charles Gross
Aslan Pharmaceuticals has received a $12M upfront payment from Zenyaku Kogyo Co. as part of a strategic licensing agreement.
July 20, 2023 | 11:59 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aslan Pharmaceuticals received a $12M upfront payment from Zenyaku Kogyo Co., which could positively impact its short-term financial position.
The upfront payment of $12M from Zenyaku Kogyo Co. to Aslan Pharmaceuticals as part of a strategic licensing agreement could provide a significant boost to Aslan's short-term financial position. This could potentially lead to a positive impact on its stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100